CorMedix's REZZAYO Prophylaxis sNDA Granted FDA Priority Review, Decision Expected Q1 2027

What happened

CorMedix announced that the FDA accepted the supplemental New Drug Application for REZZAYO (rezafungin) for prophylaxis of invasive fungal disease, filed by its global partner Mundipharma, and granted Priority Review with a target action date in Q1 2027. The submission is supported by positive topline results from the Phase III ReSPECT study announced in April, and if approved, CorMedix plans to begin promotional efforts in H2 2027. This regulatory milestone adds a potential third revenue stream to CorMedix's portfolio, which currently comprises DefenCath in the dialysis market and the recently acquired Melinta hospital anti-infective products. While the Priority Review designation shortens the approval timeline, it does not guarantee FDA approval, and any revenue contribution from this new indication would not materialize before 2028. The news independently validates the ReSPECT data but does not change the near-term investment thesis, which centers on DefenCath's utilization growth ahead of the July 2026 reimbursement step-down and Melinta integration synergies.

Implication

Investors should treat this news as a modest positive that extends the long-term growth narrative beyond dialysis without altering the core earnings trajectory. The priority review could lead to an approval decision by early 2027, potentially enabling a new hospital-based revenue stream in late 2027, but the commercial opportunity remains unproven and relatively distant. In the interim, the key risk remains the DefenCath price reset on July 1, 2026, and the company's ability to offset it with volume growth and cost synergies from Melinta. A positive approval could eventually support a higher multiple if REZZAYO demonstrates meaningful adoption, but for now the base case stays intact, with a potential rerating only if Q2 2026 ReSPECT data and DefenCath KPIs accelerate. Maintain a focus on execution milestones; the news does not justify a change in position sizing without further confirmation of the underlying business resilience.

Thesis delta

The FDA acceptance of REZZAYO sNDA with Priority Review slightly strengthens the long-term optionality of CRMD's pipeline, but it does not shift the primary investment thesis built on DefenCath's 1H26 utilization ramp and Melinta synergies. The probability of REZZAYO generating revenue by 2028 increases, yet the near-term earnings power remains unchanged and still faces the known reimbursement step-down. Consequently, the thesis delta is marginal: add REZZAYO as a potential 2027+ catalyst, but no change to the base case valuation or entry strategy.